Gene Expression Profile of Cultured Human Coronary Arterial Endothelial Cells Exposed to Serum from Chronic Kidney Disease Patients: Role of MAPK Signaling Pathway
Patients with end-stage renal disease (ESRD) are at increased risk of cardiovascular disease (CVD), such as myocardial infarction (MI). Uremic toxins and endothelial dysfunction are central to this process. In this exploratory study, we used the Affymetrix GeneChip microarray to investigate the gene expression profile in uremic serum-induced human coronary arterial endothelial cells (HCAECs) from ESRD patients with and without MI (UWI and UWOI groups) as an approach to its underlying mechanism. We also explored which pathways are involved in this process. We found 100 differentially expressed genes (DEGs) among the conditions of interest by supervised principal component analysis and hierarchical cluster analysis. The expressions of four major DEGs were validated by quantitative RT-PCR. Pathway analysis and molecular network were used to analyze the interaction and expression patterns. Ten pathways were identified as the main enriched metabolic pathways according to the transcriptome profiling analysis, which were, among others, positive regulation of inflammatory response, positive regulation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) cascade, cardiac muscle cell development, highlighting positive regulation of mitogen-activated protein kinase (MAPK) activity (<i>p</i> = 0.00016). Up- and down-regulation of genes from HCAECs exposed to uremic serum could contribute to increased endothelial dysfunction and CVD in ESRD patients. Our study suggests that inflammation and the ERK-MAPK pathway are highly enriched in kidney disease patients with MI, suggesting their role in ESRD pathology. Further studies and approaches based on MAPK pathway interfering strategies are needed to confirm these data.
Authors
- Angélica Rangel-López (ORCID: https://orcid.org/0000-0001-7040-9379)
- Sergio Juárez‐Méndez (ORCID: https://orcid.org/0000-0002-3269-329X)
- José Arellano‐Galindo (ORCID: https://orcid.org/0000-0001-7289-0821)
- Vanessa Villegas-Ruíz (ORCID: https://orcid.org/0000-0002-5441-2612)
- Cleto Álvarez-Aguilar (ORCID: https://orcid.org/0000-0002-1608-1808)
- Abraham Majluf‐Cruz (ORCID: https://orcid.org/0000-0002-7697-5790)
- Dulce María López-Sánchez (ORCID: https://orcid.org/0000-0002-7318-0618)
- Dante Amato (ORCID: https://orcid.org/0000-0002-4849-1027)
- Alfonso Méndez-Tenorio (ORCID: https://orcid.org/0000-0003-1871-4311)
- Ramón Paniagua-Sierra
- Óscar Orihuela-Rodríguez
- Sergio Zavala-Vega (ORCID: https://orcid.org/0000-0002-3010-4543)
- Ricardo López-Romero (ORCID: https://orcid.org/0000-0002-5030-5836)
- Oscar Alberto Pérez-González (ORCID: https://orcid.org/0000-0002-5672-648X)
- Minerva Mata‐Rocha (ORCID: https://orcid.org/0000-0003-0949-461X)
- Juan Manuel Mejía‐Aranguré (ORCID: https://orcid.org/0000-0001-8027-6231)
- Sara Ma Gutiérrez Torre
Institutions
- Mexican Social Security Institute (MX)
- Universidad Michoacana de San Nicolás de Hidalgo (MX)
- Secretaria de Salud (MX)
- Hospital Infantil de México Federico Gómez (MX)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- National Institute of Genomic Medicine (MX)
- Hospital de Especialidades (MX)
- Instituto Nacional de Pediatria (MX)
- Instituto Nacional de Neurología y Neurocirugía (MX)
- Instituto Politécnico Nacional (MX)
- Universidad Nacional Autónoma de México (MX)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2025-04-15
- DOI
- https://doi.org/10.3390/ijms26083732
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Instituto Mexicano del Seguro Social